Nisa Investment Advisors LLC Has $146,000 Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Nisa Investment Advisors LLC lessened its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 32.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,951 shares of the biopharmaceutical company’s stock after selling 1,894 shares during the period. Nisa Investment Advisors LLC’s holdings in Halozyme Therapeutics were worth $146,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Harbour Investments Inc. acquired a new stake in Halozyme Therapeutics during the 4th quarter worth about $51,000. Advisory Services Network LLC raised its holdings in Halozyme Therapeutics by 50.5% during the 1st quarter. Advisory Services Network LLC now owns 903 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 303 shares during the period. Belpointe Asset Management LLC raised its holdings in Halozyme Therapeutics by 42.0% during the 1st quarter. Belpointe Asset Management LLC now owns 1,238 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 366 shares during the period. Acadian Asset Management LLC acquired a new stake in Halozyme Therapeutics during the 1st quarter worth about $92,000. Finally, BOKF NA acquired a new stake in Halozyme Therapeutics during the 4th quarter worth about $201,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Up 2.2 %

Shares of HALO stock opened at $38.64 on Friday. Halozyme Therapeutics, Inc. has a 12 month low of $29.85 and a 12 month high of $45.00. The firm has a market cap of $4.91 billion, a PE ratio of 18.31, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25. The stock has a 50 day moving average of $39.56 and a 200-day moving average of $37.77. The company has a quick ratio of 5.50, a current ratio of 6.64 and a debt-to-equity ratio of 17.89.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. The business had revenue of $230.04 million for the quarter, compared to analyst estimates of $235.25 million. On average, equities analysts predict that Halozyme Therapeutics, Inc. will post 3.45 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on HALO. The Goldman Sachs Group lowered their target price on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating on the stock in a research note on Thursday, January 18th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday. StockNews.com raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 23rd. Morgan Stanley lowered their price target on Halozyme Therapeutics from $61.00 to $59.00 and set an “overweight” rating for the company in a research note on Tuesday, December 26th. Finally, TheStreet cut Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research report on Monday, January 22nd. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $53.29.

Insider Transactions at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $39.55, for a total value of $395,500.00. Following the completion of the transaction, the senior vice president now directly owns 156,558 shares in the company, valued at $6,191,868.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 30,000 shares of company stock worth $1,196,800 over the last three months. 2.40% of the stock is currently owned by insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.